Skip to main content

Find a clinical trial

AC-061A302

A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile associated diarrhea (CDAD) Mickael Aoun

AMC303-01

A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Philippe Aftimos

CA209358 / CheckMate 358

Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors. Ahmad Hussein Awada

CA209-142

CA209-142 A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer Alain Hendlisz

1367.1

An open label, Phase Ia/Ib dose finding study with BI 894999 orally administeredonce a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Ahmad Hussein Awada

IJB_2706

An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors Christiane Jungels

CIRT

CIRSE Registry for SIR-Spheres Therapy (CIRT) Patrick Flamen

LINK

An open-label dose escalation Phase I study to assess the safety and clinical activity of multiple hepatic transarterial administrations of NKR-2 in patients with unresectable liver metastases from colorectal cancer Alain Hendlisz

SHRINK

An open-label, Phase I study to assess the safety and clinical activity of multiple doses of NKR-2, administered concurrently with the neoadjuvant Folfox treatment in patients with potentially resectable liver metastases from colorectal cancer Alain Hendlisz

STRIVE

a phase 2, multicenter, randomized, double-blind study of the safety, tolerability and efficacy of intravenous CD101 vs intravenous caspofungin followed by oral fluconazole stept-down in the treatment of subjects with candidemia Mickael Aoun

EORTC 1658

Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Konstantinos Stathopoulos

GS-US-218-1227

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respiratory Syncytial Virus (RSV) Infection Mickael Aoun

Intervention dyadique

Reinforcement of onco-psychological interventions by the development of psychological support for patients and their significant others

IJB_2711

A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

IJB_2719

A Phase 1/2, Open-Label, Dose-Escalation / Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies Ahmad Hussein Awada

INCB 01158-203

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors. (INCB01158-203)

IJB_2674

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

IJB_2724

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Philippe Aftimos

CHRONOS & KAIROS

CHRONOS & KAIROS Project : Creation of a Prospective Combined Clinical and Biological Database to Capture in Parallel the Patient's Clinical History AND Tumoral Qualitative and Quantitative Changes During the Course of the Disease Alain Hendlisz

ARTemIS-Eso

Assessment of Metabolic and pathological Response to Treatment with Radio-chemotherapy (RCT) and Immunotherapy before Surgery in locally advanced Esophageal and gastro-esophageal junction cancer: ARTemIS-Eso phase I study Amelie Deleporte

Follow us!

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more